Pradalier A, Guérard des Lauriers A, Scheck F, Peraudeau P, Lacoste J P, Cajfinger F
Service de Médecine Interne IV, Centre Hospitalier Louis-Mourier, COLOMBES, France.
Pathol Biol (Paris). 1995 Nov;43(9):806-13.
In this randomised, double-blind, cross-over study the association of calcium carbasalate+metoclopramide was compared with oral dihydroergotamine mesilate in the treatment of migraine attacks. 155 patients suffering from migraine, with or without aura were analysed; the main efficacy criteria being the evolution of the headache intensity: disappearance of headache 2 hours after administration or incomplete improvement (severe to moderate headache reduced to slight headache). There was a significantly greater reduction in headache intensity following administration of CSC-METO (p < 0.001), the percentage of patients showing recovery or improvement two hours after administration being 64.5% with CSC-METO compared to 43.5% with DHE. A significantly more marked improvement following administration of CSC-METO was also observed for nausea, photophobia, phonophobia, use of analgesic treatment, impact on normal activities and overall assessment by the patient and physician. The frequency of undesirable events was weak and identical for both treatments.
在这项随机、双盲、交叉研究中，比较了卡巴匹林钙+甲氧氯普胺与口服甲磺酸二氢麦角胺治疗偏头痛发作的相关性。分析了155例患有偏头痛（有或无先兆）的患者；主要疗效标准为头痛强度的变化：给药后2小时头痛消失或改善不完全（重度至中度头痛减轻为轻度头痛）。服用卡巴匹林钙-甲氧氯普胺（CSC-METO）后头痛强度的降低更为显著（p<0.001），服用CSC-METO后两小时显示恢复或改善的患者百分比为64.5%，而服用甲磺酸二氢麦角胺（DHE）的为43.5%。服用CSC-METO后，在恶心、畏光、畏声、使用止痛治疗、对正常活动的影响以及患者和医生的总体评估方面也观察到了更显著的改善。两种治疗的不良事件发生率都很低且相同。
